Phoremost Positive logo Phoremost default logo

Raising a start-up's profile

Creating a new brand identity and language for Cambridge start-up.

The client

When PhoreMost approached KISS it was a new biotech company with a vision to bring more effective and affordable targeted medicines to patients and to drug the undruggable. PhoreMost was developing a next-generation phenotypic screening platform called SITESEEKER and needed strategic, creative and delivery support to bring the brand alive and to develop the visual assets to tell a very complicated story with clarity.

This supported the strategic goal to raise awareness amongst potential investors to secure additional funding and also interest amongst pharma and biotech companies for partnering and collaboration opportunities.

In order to be successful, it was crucial for KISS to help articulate PhoreMost’s serious credentials in the sector and to therefore catch the attention of additional potential investors and partners.

Our challenge

Getting a fledgling business ready for next phase of investment

Graphically illustrate their technology

Develop a website to achieve the objectives of the Company

The KISS solution

KISS developed a new brand identity for PhoreMost which allowed it to stand out in the crowded Life Science sector. The use of purple hues ground the brand in the LifeScience sector, important for PhoreMost’s target audiences, while at the same time, softening the brand and giving it an approachable personality.The pink hotspot communicates the company’s targeted approach to improving successful drug discovery rates.

Once a visual identity route had been agreed, KISS rolled out the identity across all corporate marketing collateral from business cards to a PowerPoint to Social Media platforms. In addition, KISS designed and built the PhoreMost website.

.

Since launching the new brand, PhoreMost, led by CEO Chris Torrance and supported by COO Jeff Roix has attracted significant investment, has strengthened its board with notable heavyweights Jonathan Milner and Hermann Hauser and has top tier partners as it advances on its visionary aim of drugging the undruggable.